Presentation is loading. Please wait.

Presentation is loading. Please wait.

Key pathways involved in the pathogenesis of pulmonary arterial hypertension: a) endothelin (ET) pathway; b) nitric oxide pathway; and c) prostacyclin.

Published byHeike Schuster Modified over 5 years ago

Similar presentations

Presentation on theme: "Key pathways involved in the pathogenesis of pulmonary arterial hypertension: a) endothelin (ET) pathway; b) nitric oxide pathway; and c) prostacyclin."— Presentation transcript:

1 Key pathways involved in the pathogenesis of pulmonary arterial hypertension: a) endothelin (ET) pathway; b) nitric oxide pathway; and c) prostacyclin (PGI2) pathway. Key pathways involved in the pathogenesis of pulmonary arterial hypertension: a) endothelin (ET) pathway; b) nitric oxide pathway; and c) prostacyclin (PGI2) pathway. ERA: ET receptor antagonist; ETA/ETB: ET receptor subtypes A and B; SMCs: smooth muscle cells; cGMP: cyclic guanosine monophosphate (GMP); PDE-5: phosphodiesterase type-5; PDE-5i: PDE-5 inhibitor; cAMP: cyclic adenosine monophosphate. Reproduced from [2] with permission from the publisher. Olivier Sitbon, and NicholasW. Morrell Eur Respir Rev 2012;21: ©2012 by European Respiratory Society

Download ppt "Key pathways involved in the pathogenesis of pulmonary arterial hypertension: a) endothelin (ET) pathway; b) nitric oxide pathway; and c) prostacyclin."

Similar presentations

From: Nitric Oxide: A Physiologic Messenger

From: Nitric Oxide: A Physiologic Messenger
Endothelium-derived mediators: the vasodilators prostacyclin (PGI2) and nitric oxide (NO) and the vasoconstrictor endothelin (ET-1). Endothelium-derived.

Endothelium-derived mediators: the vasodilators prostacyclin (PGI2) and nitric oxide (NO) and the vasoconstrictor endothelin (ET-1). Endothelium-derived.
The Relationship between Erectile Dysfunction and Lower Urinary Tract Symptoms and the Role of Phosphodiesterase Type 5 Inhibitors  Tobias S. Köhler,

The Relationship between Erectile Dysfunction and Lower Urinary Tract Symptoms and the Role of Phosphodiesterase Type 5 Inhibitors  Tobias S. Köhler,
The key pathways and classes of drugs that have been approved for the treatment of pulmonary arterial hypertension. The key pathways and classes of drugs.

The key pathways and classes of drugs that have been approved for the treatment of pulmonary arterial hypertension. The key pathways and classes of drugs.
Physiological changes in pulmonary arterial hypertension (PAH) patients which occur in response to pregnancy. Physiological changes in pulmonary arterial.

Physiological changes in pulmonary arterial hypertension (PAH) patients which occur in response to pregnancy. Physiological changes in pulmonary arterial.
Vascular endothelial dysfunction in cirrhosis

Vascular endothelial dysfunction in cirrhosis
Divya Gupta et al. JCHF 2013;1:

Divya Gupta et al. JCHF 2013;1:
The effect of sequential addition of sildenafil to first-line epoprostenol on exercise capacity measured using 6-min walk distance (6MWD) in the PACES.

The effect of sequential addition of sildenafil to first-line epoprostenol on exercise capacity measured using 6-min walk distance (6MWD) in the PACES.
Familial history of hereditary haemorrhagic telangiectasis (HHT) of the 29-yr-old patient (•) with HHT and severe pulmonary arterial hypertension (PAH).

Familial history of hereditary haemorrhagic telangiectasis (HHT) of the 29-yr-old patient (•) with HHT and severe pulmonary arterial hypertension (PAH).
Plexiform lesion from a patient with severe pulmonary hypertension demonstrating the exuberant proliferation of cells that comprise the lumen of the small.

Plexiform lesion from a patient with severe pulmonary hypertension demonstrating the exuberant proliferation of cells that comprise the lumen of the small.
Schematic diagram showing as yet unexplored pathophysiological mechanisms in pulmonary arterial hypertension (PAH). Schematic diagram showing as yet unexplored.

Schematic diagram showing as yet unexplored pathophysiological mechanisms in pulmonary arterial hypertension (PAH). Schematic diagram showing as yet unexplored.
Pathological changes of the central airways in chronic obstructive pulmonary disease. a) A central bronchus from the lung of a cigarette smoker with normal.

Pathological changes of the central airways in chronic obstructive pulmonary disease. a) A central bronchus from the lung of a cigarette smoker with normal.
The key pathological mechanisms underlying vascular changes in pulmonary hypertension (PH). The key pathological mechanisms underlying vascular changes.

The key pathological mechanisms underlying vascular changes in pulmonary hypertension (PH). The key pathological mechanisms underlying vascular changes.
Timeline of approval of therapies for pulmonary arterial hypertension.

Timeline of approval of therapies for pulmonary arterial hypertension.
An algorithm for the early diagnosis of pulmonary arterial hypertension in systemic sclerosis. An algorithm for the early diagnosis of pulmonary arterial.

An algorithm for the early diagnosis of pulmonary arterial hypertension in systemic sclerosis. An algorithm for the early diagnosis of pulmonary arterial.
Guo-Wei He, MD, DSc, David P. Taggart, FRCS 

Guo-Wei He, MD, DSc, David P. Taggart, FRCS 
Extent of interstitial lung disease (ILD) in patients with systemic sclerosis-associated ILD. A simple stratification that utilises pulmonary function.

Extent of interstitial lung disease (ILD) in patients with systemic sclerosis-associated ILD. A simple stratification that utilises pulmonary function.
Computed tomography coronary angiogram from a 43-year-old female patient with pulmonary arterial hypertension, showing compression of the left coronary.

Computed tomography coronary angiogram from a 43-year-old female patient with pulmonary arterial hypertension, showing compression of the left coronary.
Histological evidence for endothelin (ET)-1 induction of epithelial-mesenchymal transition in rat primary distal epithelial cells. a–c) ET-1 plus BQ-123,

Histological evidence for endothelin (ET)-1 induction of epithelial-mesenchymal transition in rat primary distal epithelial cells. a–c) ET-1 plus BQ-123,
Risk assessment and treat-to-target approach for pulmonary arterial hypertension. Risk assessment and treat-to-target approach for pulmonary arterial hypertension.

Risk assessment and treat-to-target approach for pulmonary arterial hypertension. Risk assessment and treat-to-target approach for pulmonary arterial hypertension.

Similar presentations

Ads by Google